3 Stories You Should Read 5/22/2020: Tara Reade, Immunity, Hydroxychloroquine
Confluence Daily is your daily news source for women in the know
In the category of: Credibility campaign
Defense lawyers look to reopen cases where Tara Reade testified as an expert
Reade stated under oath she had an undergraduate degree that her college said she never earned and appears to have exaggerated her role in Joe Biden’s office.
Reade, the former Joe Biden staffer who recently accused him of sexually assaulting her in 1993, stated she had an undergraduate degree that her college says she never earned and appears to have exaggerated her role in Biden’s office, according to trial transcripts in two court cases reviewed by POLITICO.
Six cases involving Reade’s testimony are already under review by the Sixth District Appellate Program, Executive Director Patrick McKenna told POLITICO Thursday. The state-funded office oversees appointed defense counsel in appellate cases covering four California counties, including Monterey County, where the prosecution often tapped Reade as an expert witness.
The review will determine whether the attorneys can petition a judge to review their clients’ conviction, and potentially order a new trial.
In the category of: Immunity
Coronavirus: Immune clue sparks treatment hope
They have looked at immune cells in the blood of 60 Covid-19 patients and found an apparent crash in the numbers of T-cells.
Prof Adrian Hayday from the Crick Institute said it was a “great surprise” to see what was happening with the immune cells.
“They’re trying to protect us, but the virus seems to be doing something that’s pulling the rug from under them, because their numbers have declined dramatically.
In a microlitre (0.001ml) drop of blood, normal healthy adults have between 2,000 and 4,000 T-cells, also called T lymphocytes.
In the category of: Just don’t.
Hydroxychloroquine, Hawked By Trump, Linked To Higher Risk Of Death, Study Finds
Researchers analyzed data from 671 hospitals on six continents, involving just over 96,000 patients hospitalized from Dec. 20 to April 14 who tested positive for the coronavirus. About 15,000 received some form of hydroxychloroquine or chloroquine.
“We did not observe any benefit of hydroxychloroquine or chloroquine (when used alone or in combination with a macrolide) on in-hospital outcomes, when initiated early after diagnosis of COVID-19,” the researchers concluded. “Each of the drug regimens of chloroquine or hydroxychloroquine alone or in combination with a macrolide was associated with an increased hazard for clinically significant occurrence of ventricular arrhythmias and increased risk of in-hospital death with COVID-19.”
Confluence Daily is the one place where everything comes together. The one-stop for daily news for women.
